| Dr Peter Szasz, MD, PHD | |
|
75 Francis Street, Asbii-3rd Floor, Boston, MA 02115 | |
| (647) 207-9660 | |
| Not Available |
| Full Name | Dr Peter Szasz |
|---|---|
| Gender | Male |
| Speciality | Surgery |
| Location | 75 Francis Street, Boston, Massachusetts |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1245730100 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | 273585 (Massachusetts) | Primary |
| 208600000X | Surgery | 95781 (ZZ) | Secondary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Peter Szasz, MD, PHD 375 Boylston Street, Brookline, MA 02445 Ph: (647) 207-9660 | Dr Peter Szasz, MD, PHD 75 Francis Street, Asbii-3rd Floor, Boston, MA 02115 Ph: (647) 207-9660 |
News Archive
Welichem announced that the Company has begun to enroll patients in a Phase IIa clinical trial with its lead candidate, WBI-1001. The Phase IIa clinical trial is a 12-Week, double-blinded, placebo-controlled study. The objectives of the trial are to evaluate the efficacy of the WBI-1001 cream in comparison to the vehicle and also to evaluate the safety and tolerability of the cream in patients with psoriasis.
Like an adjustable wrench that becomes the "go-to" tool because it is effective and can be used for a variety of purposes, an existing drug that can be adapted to halt the replication of different viruses would greatly expedite the treatment of different infectious diseases.
Keryx Biopharmaceuticals, Inc. reported today that the Phase 3 "X-PECT" clinical trial evaluating perifosine (KRX-0401) + capecitabine (Xeloda) in patients with refractory advanced colorectal cancer did not meet the primary endpoint of improving overall survival versus capecitabine + placebo.
Ever since discovering a decade ago that a gene altered in lung cancer regulated an enzyme used in therapies against diabetes, Reuben Shaw has wondered if drugs originally designed to treat metabolic diseases could also work against cancer.
New research from Rice University and Italy's Eugenio Medea Scientific Institute is yielding clues about hereditary spastic paraplegia (HSP), a group of inherited neurological disorders that affect about 20,000 people in the United States.
› Verified 4 days ago
Hugh G Auchincloss, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114 Phone: 617-726-2000 | |
Nicole J Look-hong, MD, MSC Surgery Medicare: Medicare Enrolled Practice Location: Massachusetts General Hospital, 55 Fruit St., Boston, MA 02114 Phone: 617-724-3868 | |
Dr. Paul Jansson, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 75 Francis St, Neville House 236a, Boston, MA 02115 Phone: 617-732-5500 | |
Vanessa Mercedes Welten, MD MPH Surgery Medicare: Medicare Enrolled Practice Location: 75 Francis St, Boston, MA 02115 Phone: 617-732-5500 | |
Dr. Joanna Wolf Etra, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 110 Francis St Ste 9b, Boston, MA 02215 Phone: 617-632-9513 | |
Jennine Putnick, MD Surgery Medicare: Medicare Enrolled Practice Location: 330 Brookline Ave, Boston, MA 02215 Phone: 617-632-9511 | |
Michael Tarnoff, M.D. Surgery Medicare: Medicare Enrolled Practice Location: 800 Washington St, Nemc Box 7105, Boston, MA 02111 Phone: 617-636-5000 |